IL2 and neoplasm: To overcome any deficiency in this regard, we administered systemic IL-2 (50-250 × 105 IU/mouse/day ×3 days prior to sacrifice) to several tumor-bearing animals of all three strains (shown as closed squares in Figures 1, 2 &3) but the proportions of Foxp3EGFP cells in these mice were unchanged.